Bluejay Diagnostics Inc

Research Bluejay Diagnostics Inc (BJDX) on Bullrun: market cap USD 947.79K. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 947.79K.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 6.85M-USD 6.23Mn/a-15.25USD 5.16MUSD 120.21KUSD 5.98M
FY2024USD 0-USD 7.72M-USD 8.13Mn/a-456.75USD 4.30MUSD 222.25KUSD 5.73M
FY2023n/a-USD 9.95M-USD 9.02Mn/a-3631.48USD 2.21MUSD 352.98KUSD 2.89M
FY2022USD 249.04K-USD 9.30M-USD 8.94M19.6%-9.22USD 10.11MUSD 430.12KUSD 11.54M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 947.79Kn/an/an/a
20252025-12-31USD 1.61Mn/an/an/a
20242024-12-31USD 2.70Mn/an/an/a
20232023-12-29USD 1.56Mn/an/an/a
20222022-12-30USD 7.30Mn/an/an/a
20212021-12-31USD 49.15Mn/an/an/a

About Bluejay Diagnostics Inc

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Bluejay Diagnostics Inc's market cap?

Bluejay Diagnostics Inc's market capitalization is USD 947.79K.

What does Bluejay Diagnostics Inc do?

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings.